Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

3 years ago

New role supports the Company’s objective to lead the industry with faster, more inclusive clinical researchRESEARCH TRIANGLE PARK, N.C., April…

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

3 years ago

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology…

Aurora Spine to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1×1 Meetings on Thursday, April 27, 2023

3 years ago

Carlsbad, California, April 25, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a…

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

3 years ago

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a…

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

3 years ago

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

3 years ago

WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical…

Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)

3 years ago

ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post…

Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships

3 years ago

Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline in oncology TORONTO, April 25,…

SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023

3 years ago

BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the…

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

3 years ago

Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in…